Aarti Drugs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2017, Payable on or Before September 15, 2017
May 23, 2017 at 06:28 am EDT
Share
Aarti Drugs Ltd. announced that the Board of Directors of the company at its meeting held on May 23, 2017, recommended final dividend of INR 1.00 per equity share of INR 10 each amounting to INR 23,857,100 for the financial year ended March 31, 2017. The directors have recommended a final dividend at the forthcoming AGM of the company to be held on August 18, 2017. The final dividend on equity shares, if approved at AGM, will be paid on or before September 15, 2017 to the members whose names appears on the company's register of members as on August 11, 2017.
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
AARTI DRUGS LIMITED 
